HC Wainwright Boosts Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target to $17.00

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) had its target price hoisted by HC Wainwright from $15.00 to $17.00 in a report issued on Monday, November 6th, MarketBeat.com reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 151.48% from the company’s current price.

A number of other equities analysts have also commented on the stock. Piper Jaffray Companies assumed coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They issued an “overweight” rating and a $14.00 price target on the stock. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research report on Saturday, September 23rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $15.15.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at $6.76 on Monday. Tetraphase Pharmaceuticals has a fifty-two week low of $3.57 and a fifty-two week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.63). The firm had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The company’s revenue was up 355.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.58) earnings per share. equities research analysts predict that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current year.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the sale, the insider now owns 8,750 shares in the company, valued at $52,762.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Tetraphase Pharmaceuticals during the 3rd quarter worth about $107,000. Brighton Jones LLC acquired a new position in Tetraphase Pharmaceuticals during the 3rd quarter worth about $108,000. UBS Group AG raised its holdings in Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares during the last quarter. AXA bought a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth about $132,000. Finally, Jane Street Group LLC bought a new stake in Tetraphase Pharmaceuticals during the 1st quarter worth about $181,000. Institutional investors and hedge funds own 47.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/hc-wainwright-boosts-tetraphase-pharmaceuticals-inc-ttph-price-target-to-17-00/1762776.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.